There are three BRAF/MEK inhibitor combinations used for treatment of BRAF V600 E positive melanomas-1) vemurafenib/cobimetinib 2) dabrafenib/trametinib and 3) encorafenib/binimetinib. Here, MAP2K7 is linked to melanoma.